Schizophrenia (SZ) is a disease that causes mental disability and affects 1% of the total population in the world. Our aim was to identify new molecular targets that would help to diagnose and treat these patients. The GSE54578 microRNA expression profile was downloaded from the Gene Expression Omnibus database that consists of peripheral blood samples of 15 first-onset SZ patients and 15 healthy controls. Principal-component analysis-based unsupervised feature extraction (FE), protein–protein interaction network, and pathway enrichment were performed, and microRNA (miRNA)-hub gene network was established. A set of seven miRNA (hsa-miR-373-5p, hsa-miR-199a-3p, hsa-miR-22-5p, hsa-miR-4711-3p, hsa-miR-3157-3p, hsa-miR-542-5p, and hsa-miR-3615) could successfully discriminate SZ patients from healthy controls with high accuracy. We identified two miRNAs (hsa-miR-373-5p and hsa-miR-199a-3p) as a signature that mostly related to SZ. These miRNAs could be potential novel biomarkers and could contribute to the clinical treatment of this disease.

中文翻译：

---

使用基于主成分分析的无监督特征提取方法评估精神分裂症中的 miRNA 表达谱。

精神分裂症 (SZ) 是一种导致精神残疾的疾病，影响着全球 1% 的人口。我们的目标是确定有助于诊断和治疗这些患者的新分子靶标。GSE54578 microRNA 表达谱是从 Gene Expression Omnibus 数据库下载的，该数据库由 15 名首发 SZ 患者和 15 名健康对照的外周血样本组成。基于主成分分析的无监督特征提取 (FE)，蛋白质–进行蛋白质相互作用网络，通路富集，建立microRNA（miRNA）-hub基因网络。一组 7 个 miRNA（hsa-miR-373-5p、hsa-miR-199a-3p、hsa-miR-22-5p、hsa-miR-4711-3p、hsa-miR-3157-3p、hsa-miR- 542-5p 和 hsa-miR-3615) 可以成功地将 SZ 患者与健康对照者高精度区分开来。我们鉴定了两种 miRNA（hsa-miR-373-5p 和 hsa-miR-199a-3p）作为与 SZ 主要相关的特征。这些 miRNA 可能是潜在的新型生物标志物，并可能有助于该疾病的临床治疗。